IMROZ
IMROZ: Phase III Study of Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone for Transplant-Ineligible, Newly Diagnosed MM

Released: June 06, 2024

Expiration: June 05, 2025

Activity

Progress
1
Course Completed